China’s Solution for Breast Cancer Screening: Xiaoji AI Takes Center Stage in Kyoto
Special Report | Global Perspective | Cutting-Edge Technology
HEADLINE NEWS / KBCCC 2026
◆ April 13, 2026 ◆ Kyoto, Japan ◆ The Premier Global Summit on Breast Cancer Consensus
From April 10-11, 2026, a profound dialogue on the future of breast health unfolded at the Kyoto Breast Cancer Consensus Conference (KBCCC 2026), hosted by the Kyoto University Graduate School of Medicine. As the world’s foremost summit on breast cancer diagnosis and treatment, the conference gathered top global experts to establish the latest international clinical guidelines. This year, the spotlight was stolen by a revolutionary technology from China: the Xiaoji AI-powered ultrasound robot for breast cancer screening.
The Kyoto Consensus: A Global Moment for Chinese AI
In a keynote address, a distinguished professor from Kyoto University introduced the Xiaoji Doctor AI Ultrasound Robot to the assembled international experts. He noted that Xiaoji’s technological prowess had “pushed the boundaries of what experts thought was possible.” This was more than a product demonstration; it was the unveiling of a “China Solution” for the well-being and breast health of women worldwide.
The Xiaoji AI robot maintains exceptionally high stability and accuracy even in environments without professional sonographers. This capacity for accessible, high-quality screening is precisely the resource most critically needed in the global fight against breast cancer today.
“The system’s high stability in non-specialist settings is a key direction for accessible AI-powered screening. It is perfectly suited for large-scale deployment in Japan’s regional medical and health check-up centers.”
— Professor Shinzo Masuda, MD, PhDDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University
From left: Prof. Shinzo Masuda (2nd), Dr. Zhenzhong Zhou, Founder & Chairman of Xiaoji AI (3rd), Dr. He Ping, Sojitz (China) (1st right).
Expert Acclaim: A Consensus That Crosses Borders
The performance of the Xiaoji Doctor AI robot earned high praise from international experts. Professor Masakazu Toi, President of the Tokyo Metropolitan Komagome Hospital, President of the Japanese Breast Cancer Society (2022-2024), and Co-Chair of the ESMO Breast Cancer Scientific Committee, along with Professor John Benson, a renowned breast cancer expert from the University of Cambridge, both expressed immense confidence in Xiaoji AI’s clinical potential.
“Xiaoji AI offers a completely new technological dimension for the early screening of breast cancer. Its level of intelligence is truly impressive.”
— Professor Masakazu ToiPresident, Tokyo Metropolitan Komagome Hospital
“This kind of portable and efficient AI system will dramatically change the healthcare landscape in resource-scarce regions.”
— Professor John BensonBreast Cancer Expert, University of Cambridge
Center: Prof. Masako Kataoka, Department of Diagnostic Radiology / Center for Preventive Medicine, Kyoto University. Right: Prof. Masakazu Toi, President of the Tokyo Metropolitan Komagome Hospital.
A Promising Future: A New Journey for Chinese AI on the Global Stage
Beyond its academic and technical acclaim, Xiaoji AI also demonstrated a deep sense of humanism. During the conference, Dr. Zhou met a breast cancer specialist from Iran. Their conversation led to a moving promise: once the war is over, the Xiaoji AI team will travel to Iran for in-depth collaboration, bringing their advanced screening technology to the women there.
From Kyoto to the world. The global expansion of Chinese AI is not merely an export of technology but a transmission of a vision for health and peace. Looking ahead, Xiaoji AI will continue to innovate and deepen its expertise in the field of AI-powered ultrasound, making accessible healthcare a reality for every woman around the world.
© 2026 Xiaoji AI International Communication Center | KBCCC 2026 Special Report